Gene editing for hepatitis b: researchers track Long-Term safety
Disease control
ENROLLING_BY_INVITATION
This study monitors 45 people with chronic hepatitis B who already received the experimental gene editing treatment PBGENE-HBV in an earlier trial. Researchers will watch for any delayed side effects over time. No new treatment is given; the goal is to understand the long-term sa…
Sponsor: Precision BioSciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC